Marc Carrier: Proud to Share the Results of the WAVe Study
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”Proud to share the results of the WAVe Study published in AjHematology
In this Canadian multicenter collaboration across six academic centers, we evaluated weight-adjusted dalteparin dosing (up to 33,000 IU/day) in patients with cancer-associated thrombosis weighing >90 kg.
Despite early study termination due to recruitment challenges — following the rapid uptake of DOACs for VTE and updated ISTH guidance removing the upper weight limit for DOAC use — our findings remain clinically relevant:
- Major bleeding: 5.3% at 30 days
- Recurrent VTE: 1.2% at 30 days
- No significant drug accumulation (based on anti-Xa levels)
These results suggest that weight-adjusted LMWH remains a safe and effective option for selected patients with cancer and obesity, particularly those at higher bleeding risk or with contraindications to DOACs.”
Read the full article here.
Article: A Multicenter Prospective Cohort Study on the Use of Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism—The WAVe Study
Authors: Tzu-Fei Wang, Erik Yeo, Peter L. Gross, Chantal Séguin, Cynthia Wu, Sudeep Shivakumar, Ranjeeta Mallick, Aurélien Delluc, Julien D’Astous, Miriam Kimpton, Guillaume Roberge, Deborah M. Siegal, Tobias Tritschler, Grégoire Le Gal, Marc Carrier

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 14, 2026, 00:23Saji Kumar: The Role of Agentic AI in Blood Bank Inventory Coordination
-
Nov 14, 2026, 00:04Carlos A. Metidieri Menegozzo: The First Priority in Trauma Transfusion May Be Time to First Blood Product
-
Nov 13, 2026, 23:43Alamgir Hosen Ronit: Corrected Platelet Count in EDTA Induced Platelet Aggregation
-
Nov 13, 2026, 23:32Evi Loos: Can PRP Improve Pain in Thumb Base Osteoarthritis?
-
Nov 13, 2026, 23:10Cesar de Almeida Neto: Digital Connectivity Can Transform Plateletpheresis Practice
-
Nov 13, 2026, 23:10Chien-Wen Liew: Where PRP Actually Sits in the Evidence
-
Nov 13, 2026, 23:08Erika Koppers: Continuing the Collaborative Journey Towards Equitable Haemophilia Care in South Africa
-
Nov 13, 2026, 23:06Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A
-
Nov 13, 2026, 22:57Rolf Bekendam: Moderating a Conversation With Experts on Rare Bleeding Disorders